Broadwood Partners, L.P.'s Form 4 filing
Lineage Cell Therapeutics, Inc.LCTX · filed Feb 8, 2024
- Accession no.
- 0000919574-24-000757
- Filed
- Feb 8, 2024, 6:58 PM ET
- Trade date
- Feb 6, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $7.00M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Broadwood Partners, L.P.CIK 0001278386 | Director, 10% Owner |
| Bradsher Neal CCIK 0001278388 | Director, 10% Owner |
| Broadwood Capital IncCIK 0001278387 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 6, 2024 | Common Shares | PPurchaseAcquired | +6,730,770 | $1.04F2 | +$7,000,000.8 | 41,666,255 | Direct | |
| Feb 6, 2024 | Common Shares | PPurchaseAcquired | 0 | $0.00 | $0 | 41,666,255 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
On February 6, 2024, Broadwood Partners entered into a Stock Purchase Agreement with Lineage Cell Therapeutics, Inc. (the "Issuer") pursuant to which Broadwood Partners agreed to acquire 6,730,770 shares of the Issuer's Common Stock, no par value (the "Common Shares"), from the Issuer in its registered direct offering for a total purchase price of $7,000,000.80, or $1.04 per Common Share.
Referenced by the price of 1 transaction in Table I.